### **PIONEER Patient-Reported Outcome** Measures (PROMs)

The three experts Maria Monica Ratti, Elena Silvia Sisca, and Alexandra Derevianko give an insight into their work on standardising the assessment of Patient-Reported Outcome Measures in localised and metastatic prostate cancer (PCa), and explain what PROMS are, why it is important to standardize their assessment, what the outcome of their work is, and what they could conclude at the end.

### First of all, please briefly introduce yourselves and your role in the work on the standardisation of the PROMs?

**Maria Monica Ratti:** "I am Maria Monica Ratti a clinical psychologist, psychotherapist, PhD, research fellow and Lecturer of the Faculty of Medicine and Surgery at Vita-Salute San Raffaele University in Milan. I have followed and collaborated in this project since 2017, actively participating in all the different phases. I have followed both the PROMs selection project for patients with localized prostate cancer and the PROMs selection and detection project for patients with metastatic prostate cancer."

**Elena Silvia Sisca:** "I am Elena Silvia Sisca, psychologist, and I followed both projects, helping in bibliographical research, in the analysis of scientific literature and in the subsequent psychometric analysis of the different PROMs identified and used with both patients with localized prostate cancer and patients with metastatic prostate cancer."

**Alexandra Derevianko:** "I am Alexandra Derevianko, psychologist, in both projects presented. My role in this works was to help during the entire process of identification, selection and assessment of the different PROMs."

### <u>Click here to read the PIONEER</u> <u>PROMs publication in Eur Urology</u> <u>Oncology</u>

EUROPEAN UROLOGY ONCOLOGY 5 (2022) 153-163	
vailable at www.sciencedirect.com ournal homepage: euoncology.europeanurology.com	E DEROFEAN UROLOGY ONCOLOG
eau	
European Association of Urology	APRess Internet

Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review

Maria Monica Ratti<sup>®A,1</sup>, Gorgio Gandaglia<sup>\*-1,1</sup>, Eugenia Alleva<sup>\*</sup>, Luca Leardini<sup>®</sup>, Elena Silvia Sisca<sup>®</sup>, Alexandra Derevianko<sup>®</sup>, Federica Furnari<sup>®</sup>, Serena Mazzoleni Ferraccini<sup>®</sup>, Kathraina Beyer<sup>4</sup>, Charlotte Moss<sup>®</sup>, Francesco Pellegrino<sup>®</sup>, Gabriele Sorce<sup>®</sup>, Francesco Baletta<sup>†</sup>, Simon Scuderi<sup>\*</sup>, Muhammad Imran Omar<sup>\*</sup>, Steven MacLennan<sup>®</sup>, Paula R. Williamson<sup>†</sup>, Jihong Zong<sup>®</sup>, Sara J. MacLennan<sup>®</sup>, Nicolias Motte<sup>\*</sup>, Philip Cornford<sup>\*</sup>, Olaekan Lee Alyegbasi<sup>†</sup>, Mikek Van Henerityk<sup>\*</sup>, James NDW<sup>\*</sup>, Aberto Brizman<sup>†</sup>, an budi die HONEER Consortium<sup>2</sup>

## **PIONEER PROMs-2**

#### Can you briefly summarise what PROMs exactly are?

"Patient-Reported Outcome Measures (PROMs) are important tools used to understand patientfocused outcomes from care. They are questionnaires that, once filled out by the patient, are used to create a score and this score should reflect an underlying construct (for example, urinary function)."

#### Why is it important to standardize the assessment of PROMs?

"Actually, there are several reasons. First of all, using the same tools to measure the main domains of results ensures less heterogeneity in the evidence base. The use of common outcome measurement instruments will facilitate the interpretation of the evidence across different Randomized Controlled Trials and will facilitate to summarize evidence meta-analyses with a consequent impact on recommendation-making in clinical guidelines.

Furthermore, the use of the same measures in routine clinical practice and other real-world evidence data sources will facilitate the integration and analysis in Big Data platforms such as the one of PIONEER.

Finally, standardization has positive effects on the patient as the use of good psychometric tools would allow to better measure the constructs of interest and adopt more specific interventions aimed at improving the well-being of the individual."

#### What is the outcome of your analysis and what are your conclusions?

""We worked on two different patient populations: with localized PCa patients and with metastatic PCa patients. Regarding the first target, we found out that the EORTC QLQ-30 and the EORTC-PR25 should be used in both research and routine care settings to measure the core domains of urinary, bowel, and sexual function, hormonal symptoms and HRQoL. Instead, regarding the second population of patients, we found out that the use of BPI and FACT-P in mPCa patients is supported by their high content validity and internal consistency, although the number of studies evaluating the measurement properties of each instrument is limited."

**Click below to** listen to Dr. Steven MacLennan and Prof. Mieke Van Hemelrijck explain what core outcome sets are and why they are important. Followed by Dr. Elena Sisca and Dr. Monica Ratti discussing patient reported outcome measures and their impact on clinical research and patient care.



# **PIONEER PROMs - 3**

#### What was your motivation in the work on the PROMs?

We wanted to make evident the importance of psychological variable during the process of treatment. The evaluation of Quality of Life played a key role both for patients and doctors.



**Dr. Elena Silvia Sisca** Department of Medicine and Surgery, Vita Salute San Raffaele University, Milan, Italy

#### Dr. Alexandra Derevianko

Department of Clinical and Health Psychology, IRCCS San Raffaele Hospital, Milan, Italy



#### Dr. Maria Monica Ratti

Department of Medicine and Surgery, Vita Salute San Raffaele University, Milan, Italy Department of Clinical and Health Psychology, IRCCS San Raffaele Hospital, Milan, Italy